A research team from Mass General and MIT’s Koch Institute for Integrative Cancer Research are working on a new type of polymer gel that could allow swallowed medical devices or capsules to safely act inside the body over the course of days, weeks or even months.
Improving the safety of slow-release medications could open the door for devices that control hunger in patients with obesity, help to diagnose gastrointestinal issues and extend the effects of drugs.
Long-term devices are not currently in wide use because of the potential for causing an intestinal blockage when the device reaches the small intestine.
However, this new gel is designed to break down upon entering the small intestine. Giovanni Traverso, MBBCh, PhD, of the Department of Gastroenterology at Mass General, is co-senior author of the study.
After receiving life-saving surgery for an acute aortic dissection (AAD) at Mass General a few years ago, a former patient is helping to fund research into this rare but extremely life-threatening condition.
(Above, Mark Lindsay, MD, PhD, is conducting a study to search for the genetic underpinnings of acute aortic dissection.)
An AAD begins with a tear in the inner layer of the artery. This tear than allows
blood to leak between layers of the artery, increasing the risk of an aortic rupture.
Chris Toomey, who suffered an AAD and survived following a 10-hour operation and a medically induced coma that lasted more than a week, is now helping to fund a large scale collection of genetic samples from people who have also experienced AAD, with the hope of generating better predictive tests and therapeutic strategies.
The long term, multi-center study is being led by Mark Lindsay, MD, PhD (pictured above).
Researchers from the Mass General Research Institute have used an innovative approach to pinpoint two locations on the human genome that influence the rate at which Huntington’s disease (HD), a debilitating neurodegenerative disorder, develops in those carrying the HD gene defect.
By studying the samples from more than 4,000 HD patients, researchers were able to identify two genetic variants in areas distinct from the mutated gene that causes the disease.
These variants were more common in HD patients who developed symptoms at atypical times—either earlier or later than expected.
The findings imply that these genetic differences can alter the timing of the onset of the disease, which in turn could help devise ways to start treatment or preventative measures before symptoms appear.
James Gusella, PhD, director of the Center for Human Genetic Research at Mass General, is corresponding author of the report.
Massachusetts General Hospital researcher Denise Faustman, MD, PhD, has made a promising advance in her 20-year quest to cure type 1 diabetes by receiving FDA approval to test an old tuberculosis vaccine that may also treat diabetes.
Afternoon clouds and surrounding buildings are reflected in the mirrored windows of the Richard B. Simches Research Building at Massachusetts General Hospital. The Simches building is home to five thematic research centers, including:
Did you know that Mass General has an official “writer-in-residence?” Primary care physician Suzanne Koven, MD, is first to hold the role in the hospital’s 200+ year history.
Koven, whose work frequently appears in the Boston Globe and other publications, has observed that medicine’s crucial element—the clinician-patient relationship—has become threatened as the profession becomes increasingly technology-driven. She and
other physicians believe that integrating creative arts such as writing, art and music with the practice of medicine can help reduce physician burnout, foster empathy and enhance patient-doctor communication.
**Koven will be appearing at the Paul S. Rusell, MD, Museum along with WBZ-TV medical reporter Mallika Marshall to talk about the dual challenges of practicing medicine and reporting on medicine. The event is part of the Women in Medicine series sponsored by the Mass General Research Institute.**
A new Mass General research study suggests that physicians who take a more active role in connecting high-risk, longtime smokers with resources to help them quit can significantly improve their patients’ success at becoming smoke-free.
The study found that patients who receive annual lung cancer screenings due to high-risk smoking (averaging a pack a day for 30+ years) were 40% more likely to attempt quitting if their physicians provided them with direct assistance, such as connections to a treatment program, recommending or prescribing nicotine replacements or pharmaceutical aids, and then following up on those recommendations.
Of the group who agreed to try quitting, the chances of successful quitting increased by 46% with this active physician intervention. Elyse Park, PhD, of the Mass General Tobacco Treatment Center was lead author of the study.
A Mass General research study published earlier this year found—for the first time—evidence of neuroinflammation in the brain in patients with chronic pain. The study showed that levels of an inflammation- linked protein were elevated in regions of the brain known to be involved in the transmission of pain.
The discovery could make it possible to explore new treatments for chronic pain and
to find an objective way to measure the presence and/or intensity of chronic pain.
The inability to objectively measure chronic pain has been one of the most frustrating limitations on chronic pain treatment and research. Marco Loggia, PhD, of the Martinos Center for Biomedical Imaging is the lead author
of the study.